Lorraine Portelance, MD

Cancer Focus:
Endometrial (Uterine) Cancer, Ovarian Cancer, Proton Therapy, Rectal Cancer, Vaginal Cancer, Vulvar Cancer

Dr. Lorraine Portelance received her medical degree from the University of Montreal in Quebec, Canada, where she also completed her residency in Radiation Oncology. She went on to complete a fellowship in Radiation Oncology and Gynecologic Cancer Management at the Mallinckrodt Institute of Radiology in St. Louis, Missouri.

Currently, she serves as Vice Chair and Clinical Division Chief in the Department of Radiation Oncology at Moffitt Cancer Center. Before joining Moffitt, Dr. Portelance was a Professor of Radiation Oncology at the University of Miami Miller School of Medicine.

Dr. Portelance specializes in the treatment of gynecologic and gastrointestinal cancers. A leader in the field, she has helped advance radiation therapy techniques that reduce toxicity and improve disease control. She is internationally recognized for her contributions to clinical trials and her dedication to evidence-based, patient-centered care.

A pioneer in on-board adaptive MR-guided radiation therapy, Dr. Portelance has led innovations in treating gynecologic and GI cancers with greater precision and personalization. She is also a dedicated clinical trialist, actively supporting Moffitt’s collaboration with national research cooperative groups such as NRG Oncology and Alliance. She works closely with the gynecologic oncology team of experts to develop research initiatives to improve outcomes for women with gynecologic cancers.

Her ongoing research focuses on evaluating dose-escalated MR-guided radiation therapy for organ-preserving treatment in patients with locally advanced rectal cancer.

Clinical Trial 24206
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
Condition: Gynecological Tumor
Intervention: EBRT (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Saini AS, Kumar R, Bustillos I, Garg A, Peterson J, Portelance L, Tharp M, Yamoah K, Grass GD, Frakes JM, Hoffe SE, Hunt DC, Saini AS, Fernandez DC, Ennis RD, Rishi A. Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework. Brachytherapy. 2026 Jun.25(4):664-672. Pubmedid: 42103556.
• Fields EC, Bosch WR, Albuquerque KV, Bhatia R, Chino J, Dyer B, Erickson B, Fabian D, Gaffney D, Glaser S, Han K, Hathout L, Hsu IC, Jegadeesh N, Kahn J, Kidd E, Klopp A, Leung E, Lin L, Ludwig M, Ma T, Mell L, Mayadev J, Petersen I, Portelance L, Rash D, Taunk N, Viswanathan A, Wolfson A, Yashar C, Yeung A, Yoshida E, Fisher CM. Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity Modulated Radiation Therapy for Intact Cervical Cancer: An Update. Pract Radiat Oncol. 2025 Mar.15(2):171-179. Pubmedid: 39547646. Pmcid: PMC11954667.
• Portelance L, Asher D, Llorente R, Mellon E, Wolfson A, Simpson G, Baikovitz J, Dogan N, Padgett KR. Potential to reduce margins and Shrink targets in patients with intact cervical cancer treated on An MRI guided radiation therapy (MRgRT) system. Phys Med. 2025 Jan.129:104869. Pubmedid: 39671905.
• Rivera A, Barrios DM, Herbach E, Kahn JM, Williams VM, Mehta KJ, Wolfson A, Portelance L, Kamrava M. Analgesia and Anesthesia Practice Patterns for Gynecologic Brachytherapy Procedures and Potential Impact on Women's Procedural Experience: A National Survey. Int J Radiat Oncol Biol Phys. 2025 Jan.121(1):118-127. Pubmedid: 39067485.
• Ugurluer G, Schneiders FL, Corradini S, Boldrini L, Kotecha R, Kelly P, Portelance L, Camilleri P, Ben-David MA, Poiset S, Marschner SN, Panza G, Kutuk T, Palacios MA, Castelluccia A, Zoto Mustafayev T, Atalar B, Senan S, Ozyar E. Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases. Clin Transl Radiat Oncol. 2024 May.46:100756. Pubmedid: 38450219. Pmcid: PMC10915494.
• Chuong MD, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, Padgett KR, Zaki B, Zhang R, Kim H, Henke LE, Price AT, Mancias JD, Williams CL, Ng J, Pennell R, Raphael Pfeffer M, Levin D, Mueller AC, Mooney KE, Kelly P, Shah AP, Boldrini L, Placidi L, Fuss M, Jitendra Parikh P. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study. Radiother Oncol. 2024 Feb.191:110064. Pubmedid: 38135187.
• Parikh PJ, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, Padgett KR, Zaki B, Zhang R, Kim H, Henke LE, Price AT, Mancias JD, Williams CL, Ng J, Pennell R, Pfeffer MR, Levin D, Mueller AC, Mooney KE, Kelly P, Shah AP, Boldrini L, Placidi L, Fuss M, Chuong MD. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023 Nov.117(4):799-808. Pubmedid: 37210048.
• Morgan O, Schnur J, Caban-Martinez AJ, Duenas-Lopez M, Huang M, Portelance L, Elkhadem A, Marshall DC. A qualitative analysis of female patient perspectives on physician communication regarding sexual dysfunction associated with pelvic radiotherapy. J Sex Med. 2023 May.20(6):813-820. Pubmedid: 37037772. Pmcid: PMC10230644.
• Bell JB, Portelance L, de la Zerda A, Wolfson A. Practical Considerations During Brachytherapy Applicator Placement for Locally Advanced Cervical Cancer. Pract Radiat Oncol. 2023 Jul.13(4):328-333. Pubmedid: 36724848.
• Chuong MD, Clark MA, Henke LE, Kishan AU, Portelance L, Parikh PJ, Bassetti MF, Nagar H, Rosenberg SA, Mehta MP, Refaat T, Rineer JM, Smith A, Seung S, Zaki BI, Fuss M, Mak RH. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments. Clin Transl Radiat Oncol. 2023 Jan.38:161-168. Pubmedid: 36466748. Pmcid: PMC9712826.
• Taswell CS, Studenski M, Pennix T, Stover B, Georgiou M, Venkat S, Jones P, Zikria J, Thornton L, Yechieli R, Mohan P, Portelance L, Spieler B. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes. Cancers (Basel). 2023 Jan.15(3). Pubmedid: 36765603. Pmcid: PMC9913422.
• Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023 Feb.41(6):1285-1295. Pubmedid: 36260832. Pmcid: PMC9940937.
• Duenas-Lopez M, Morgan O, Marshall DC, Carney L, Caban-Martinez A, Huang M, Portelance L, Schnur J. Cuban American Perspectives on Sexual Dysfunction Following Pelvic Radiotherapy: A Qualitative Study. Sex Disabil. 2023 Dec.41(4):757-768. Pubmedid: 38948491. Pmcid: PMC11213550.
• Jin WH, Simpson GN, Dogan N, Spieler B, Portelance L, Yang F, Ford JC. MRI-based delta-radiomic features for prediction of local control in liver lesions treated with stereotactic body radiation therapy. Sci Rep. 2022 Nov.12(1):18631. Pubmedid: 36329116. Pmcid: PMC9633752.
• Roy M, Finch L, Kwon D, Jordan SE, Yadegarynia S, Wolfson AH, Slomovitz B, Portelance L, Huang M. Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population. Int J Gynecol Cancer. 2022 Nov.32(11):1387-1394. Pubmedid: 36198435. Pmcid: PMC9664089.
• Breto AL, Spieler B, Zavala-Romero O, Alhusseini M, Patel NV, Asher DA, Xu IR, Baikovitz JB, Mellon EA, Ford JC, Stoyanova R, Portelance L. Deep Learning for Per-Fraction Automatic Segmentation of Gross Tumor Volume (GTV) and Organs at Risk (OARs) in Adaptive Radiotherapy of Cervical Cancer. Front Oncol. 2022 May.12:854349. Pubmedid: 35664789. Pmcid: PMC9159296.
• Kim H, Lee P, Tree AC, Chuong MD, Raldow AC, Kishan AU, Fuller CD, Rosenberg SA, Hall WA, Chie EK, Portelance L. Adaptive Radiation Therapy Physician Guidelines: Recommendations From an Expert Users' Panel. Pract Radiat Oncol. 2022 Jun.12(5):e355-e362. Pubmedid: 35644469.
• Williamson CW, Sirák I, Xu R, Portelance L, Wei L, Tarnawski R, Mahantshetty U, Heide ES, Yashar CM, McHale MT, Bosch W, Lowenstein J, Saenz CC, Plaxe S, Eskander R, Einck J, Mundt AJ, Mayadev J, Mell LK. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial. Int J Radiat Oncol Biol Phys. 2022 Jan.112(1):169-178. Pubmedid: 34419564. Pmcid: PMC8688221.
• Hu P, Li X, Liu W, Yan B, Xue X, Yang F, Ford JC, Portelance L, Yang Y. Dosimetry impact of gating latency in cine magnetic resonance image guided breath-hold pancreatic cancer radiotherapy. Phys Med Biol. 2022 Feb.67(5). Pubmedid: 35144247.
• Sherertz T, Jhingran A, Biagioli M, Gaffney D, Elshaikh M, Coleman RL, Harkenrider M, Kidd EA, Jolly S, Yashar C, Portelance L, Wahl A, Venkatesan A, Li L, Small W. Executive summary of the American Radium Society appropriate use criteria for management of uterine clear cell and serous carcinomas. Int J Gynecol Cancer. 2022 Dec.32(12):1549-1554. Pubmedid: 36423958.
• Simpson G, Jin W, Spieler B, Portelance L, Mellon E, Kwon D, Ford JC, Dogan N. Predictive Value of Delta-Radiomics Texture Features in 0.35 Tesla Magnetic Resonance Setup Images Acquired During Stereotactic Ablative Radiotherapy of Pancreatic Cancer. Front Oncol. 2022 Apr.12:807725. Pubmedid: 35515129. Pmcid: PMC9063004.
• Georgiou MF, Kuker RA, Studenski MT, Ahlman PP, Witte M, Portelance L. Lung shunt fraction calculation using 99mTc-MAA SPECT/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors. EJNMMI Res. 2021 Sep.11(1):96. Pubmedid: 34585259. Pmcid: PMC8479035.
• Garcia-Soto AE, McKenzie ND, Whicker ME, Pearson JM, Jimenez EA, Portelance L, Hu JJ, Lucci JA, Qureshi R, Kossenkov A, Schwartz L, Mills GB, Maity A, Lin LL, Simpkins F. Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer. 2021 Jul.127(13):2279-2293. Pubmedid: 33932031. Pmcid: PMC8252376.
• Small W, Bosch WR, Harkenrider MM, Strauss JB, Abu-Rustum N, Albuquerque KV, Beriwal S, Creutzberg CL, Eifel PJ, Erickson BA, Fyles AW, Hentz CL, Jhingran A, Klopp AH, Kunos CA, Mell LK, Portelance L, Powell ME, Viswanathan AN, Yacoub JH, Yashar CM, Winter KA, Gaffney DK. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):413-424. Pubmedid: 32905846. Pmcid: PMC7856050.
• Portelance L, Corradini S, Erickson B, Lalondrelle S, Padgett K, van der Leij F, van Lier A, Jürgenliemk-Schulz I. Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers. Front Oncol. 2021 Aug.11:628131. Pubmedid: 34513656. Pmcid: PMC8429611.
• Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Phys Med. 2020 Sep.77:54-63. Pubmedid: 32781388.
• Grant SR, Noticewala SS, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Gunn GB, Fuller CD, Thomas CR, Portelance L, Ludmir EB. Non-English language validation of patient-reported outcome measures in cancer clinical trials. Support Care Cancer. 2020 Jun.28(6):2503-2505. Pubmedid: 32189098.
• Simpson G, Ford JC, Llorente R, Portelance L, Yang F, Mellon EA, Dogan N. Impact of quantization algorithm and number of gray level intensities on variability and repeatability of low field strength magnetic resonance image-based radiomics texture features. Phys Med. 2020 Dec.80:209-220. Pubmedid: 33190077.
• Simpson G, Spieler B, Dogan N, Portelance L, Mellon EA, Kwon D, Ford JC, Yang F. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study. Med Phys. 2020 Aug.47(8):3682-3690. Pubmedid: 32329904.
• Elshaikh MA, Modh A, Jhingran A, Biagioli MC, Coleman RL, Gaffney DK, Harkenrider MM, Heskett K, Jolly S, Kidd E, Lee LJ, Li L, Portelance L, Sherertz T, Venkatessan AM, Wahl AO, Yashar CM, Small W. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma. Gynecol Oncol. 2020 Aug.158(2):460-466. Pubmedid: 32475772.
• Jordan SE, Schlumbrecht M, George S, Pearson JM, Wolfson A, Slomovitz B, Portelance L, Huang M. The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population. Gynecol Oncol. 2020 Apr.157(1):167-172. Pubmedid: 31983517.
• Mehta S, Ramey SJ, Kwon D, Rich BJ, Ahmed AA, Wolfson A, Yechieli R, Portelance L, Mellon EA. Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus. J Gastrointest Oncol. 2020 Apr.11(2):277-290. Pubmedid: 32399269. Pmcid: PMC7212100.
• Rudra S, Jiang N, Rosenberg SA, Olsen JR, Roach MC, Wan L, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019 May.8(5):2123-2132. Pubmedid: 30932367. Pmcid: PMC6536981.
• Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, Hamilton B, Herman J, Kappadath SC, Leung T, Portelance L, Sze D, Garin E. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019 Jul.46(8):1695-1704. Pubmedid: 31098749.
• El-Bared N, Portelance L, Spieler BO, Kwon D, Padgett KR, Brown KM, Mellon EA. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. Pract Radiat Oncol. 2019 Jan.9(1):e46-e54. Pubmedid: 30149192.
• Mehta S, Farnia B, de la Zerda A, Rahimi R, Wolfson A, Portelance L. Dosimetric effects of the Smit sleeve on high-dose-rate brachytherapy tandem and ovoids plans for patients with locally advanced cervical cancer. J Contemp Brachytherapy. 2019 Dec.11(6):584-588. Pubmedid: 31969918. Pmcid: PMC6964339.
• Hall WA, Heerkens HD, Paulson ES, Meijer GJ, Kotte AN, Knechtges P, Parikh PJ, Bassetti MF, Lee P, Aitken KL, Palta M, Myrehaug S, Koay EJ, Portelance L, Ben-Josef E, Erickson BA. Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conference. Pract Radiat Oncol. 2018 Sep.8(2):107-115. Pubmedid: 29426692.
• Ramey SJ, Padgett KR, Lamichhane N, Neboori HJ, Kwon D, Mellon EA, Brown K, Duffy M, Victoria J, Dogan N, Portelance L. Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided Tri-60Co unit, MR-guided LINAC, and conventional LINAC-based plans. Pract Radiat Oncol. 2018 Nov.8(5):e312-e321. Pubmedid: 29703704.
• Asher D, Padgett KR, Llorente RE, Farnia BS, Ford JC, Gajjar SR, Mehta S, Simpson GN, Dogan N, Portelance L. Magnetic Resonance-guided External Beam Radiation and Brachytherapy for a Patient with Intact Cervical Cancer. Cureus. 2018 May.10(5):e2577. Pubmedid: 29984119. Pmcid: PMC6034762.
• Mihaylov IB, Mellon EA, Yechieli R, Portelance L. Automated inverse optimization facilitates lower doses to normal tissue in pancreatic stereotactic body radiotherapy. PLoS One. 2018 Jan.13(1):e0191036. Pubmedid: 29351303. Pmcid: PMC5774747.
• Ramey SJ, Rich BJ, Kwon D, Mellon EA, Wolfson A, Portelance L, Yechieli R. Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis. J Gastrointest Oncol. 2018 Dec.9(6):1109-1126. Pubmedid: 30603130. Pmcid: PMC6286932.
• Ramey SJ, Asher D, Kwon D, Ahmed AA, Wolfson AH, Yechieli R, Portelance L. Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact. Gynecol Oncol. 2018 Apr.149(1):53-62. Pubmedid: 29605051.
• Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2016 Sep.15(6):667-673. Pubmedid: 26412296.
• Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016 Nov.39(11):1580-1588. Pubmedid: 27586657.
• Wolfson AH, Reis IM, Portelance L, Diaz DA, Zhao W, Gibb RK. Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. Gynecol Oncol. 2016 May.141(2):255-259. Pubmedid: 26970567.
• Gaffney DK, King B, Viswanathan AN, Barkati M, Beriwal S, Eifel P, Erickson B, Fyles A, Goulart J, Harkenrider M, Jhingran A, Klopp A, Koh WJ, Lim K, Petersen I, Portelance L, Small W, Stewart A, Wiebe E, Wolfson A, Yashar C, Bosch W. Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Jul.95(4):1191-1200. Pubmedid: 27130794. Pmcid: PMC5189987.
• Lim K, Erickson B, Jürgenliemk-Schulz IM, Gaffney D, Creutzberg CL, Viswanathan A, Portelance L, Beriwal S, Wolfson A, Bosch W, De Los Santos J, Yashar C, Jhingran A, Varia M, El Naqa I, King B, Fyles A. Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. Pract Radiat Oncol. 2015 Nov.5(6):e557-e565. Pubmedid: 26432679. Pmcid: PMC4884648.
• Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul.121(13):2156-2163. Pubmedid: 25847373. Pmcid: PMC4685031.
• Jones E, Beriwal S, Beyer D, Chino J, Jhingran A, Lee L, Michalski J, Mundt AJ, Patton C, Petersen I, Portelance L, Schwarz JK, McCloskey S. An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive summary. Adv Radiat Oncol. 2015 Dec.1(1):26-34. Pubmedid: 28799571. Pmcid: PMC5506720.
• Viswanathan AN, Erickson B, Gaffney DK, Beriwal S, Bhatia SK, Lee Burnett O, D'Souza DP, Patil N, Haddock MG, Jhingran A, Jones EL, Kunos CA, Lee LJ, Lin LL, Mayr NA, Petersen I, Petric P, Portelance L, Small W, Strauss JB, Townamchai K, Wolfson AH, Yashar CM, Bosch W. Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014 Oct.90(2):320-328. Pubmedid: 25304792. Pmcid: PMC4194192.
• Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. Int J Gynecol Cancer. 2014 Jun.24(5):956-962. Pubmedid: 24819663. Pmcid: PMC4808297.
• Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W, Gaur R, Jhingran A. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013 May.86(1):83-90. Pubmedid: 23582248. Pmcid: PMC4572833.
• Bloemers MC, Portelance L, Ruo R, Parker W, Souhami L. A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy. Med Dosim. 2013 Jan.37(3):310-313. Pubmedid: 22317848.
• Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, Souhami L, Small W, Berk L, Gaffney D. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012 Sep.84(1):e23-e28. Pubmedid: 22543211.
• Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May.12:199. Pubmedid: 22642850. Pmcid: PMC3404979.
• Alfieri J, Portelance L, Souhami L, Steinert Y, McLeod P, Gallant F, Artho G. Development and impact evaluation of an e-learning radiation oncology module. Int J Radiat Oncol Biol Phys. 2012 Mar.82(3):e573-e580. Pubmedid: 22024203.
• Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W, Gaffney D, Viswanathan AN, Michalski JM. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012 Jul.83(3):e353-e362. Pubmedid: 22483697. Pmcid: PMC3904368.
• Pavamani S, D'Souza DP, Portelance L, Craighead PS, Pearce AG, Traptow LL, Doll CM. Image-guided brachytherapy for cervical cancer: a Canadian Brachytherapy Group survey. Brachytherapy. 2012 Jan.10(5):345-351. Pubmedid: 21345744.
• Bloemers MC, Portelance L, Legler C, Renaud MC, Tan SL. Preservation of ovarian function by ovarian transposition prior to concurrent chemotherapy and pelvic radiation for cervical cancer. A case report and review of the literature. Eur J Gynaecol Oncol. 2010 Jun.31(2):194-197. Pubmedid: 20527239.
• Al-Halabi H, Portelance L, Duclos M, Reniers B, Bahoric B, Souhami L. Cone beam CT-based three-dimensional planning in high-dose-rate brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2010 Jul.77(4):1092-1097. Pubmedid: 19879059.
• Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble EL. Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study. Int J Gynecol Cancer. 2009 Jan.19(1):163-167. Pubmedid: 19258960.
• Bahig H, Portelance L, Legler C, Gilbert L, Souhami L. Small cell carcinoma of the endometrium: report of a case and review of the literature. Minerva Ginecol. 2009 Aug.61(4):365-369. Pubmedid: 19745801.
• Patone H, Souhami L, Parker W, Evans M, Duclos M, Portelance L. A dosimetric comparison of two high-dose-rate brachytherapy planning systems in cervix cancer: standardized template planning vs. computerized treatment planning. Brachytherapy. 2008 Nov.7(3):254-259. Pubmedid: 18579447.
• Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008 Jun.71(2):428-434. Pubmedid: 18037584. Pmcid: PMC2752724.
• Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007 Oct.2(10):927-932. Pubmedid: 17909355.
• Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Pötter R, Colombo A, Randall M, Mirza MR, Trimble EL. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2007 Jun.68(2):485-490. Pubmedid: 17336465.
• Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L. Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer. Int J Radiat Oncol Biol Phys. 2007 Aug.68(5):1438-1445. Pubmedid: 17418961.
• Vuong T, Kopek N, Ducruet T, Portelance L, Faria S, Bahoric B, Devic S. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Apr.67(5):1394-1400. Pubmedid: 17276620.
• Faria SL, Souhami L, Portelance L, Duclos M, Vuong T, Small D, Freeman CR. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Radiat Oncol. 2006 Nov.1:42. Pubmedid: 17078878. Pmcid: PMC1635719.
• Shenouda G, Mehio A, Souhami L, Duclos M, Portelance L, Belenkov A, Chow T. Erythropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. Int J Gynecol Cancer. 2006 Mar.16(2):752-756. Pubmedid: 16681756.
• Niazi TM, Souhami L, Portelance L, Bahoric B, Gilbert L, Stanimir G. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov.63(4):1108-1113. Pubmedid: 16099598.
• Souhami L, Corns R, Duclos M, Portelance L, Bahoric B, Stanimir G. Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. Gynecol Oncol. 2005 May.97(2):508-513. Pubmedid: 15863152.
• Vuong T, Franco E, Lehnert S, Lambert C, Portelance L, Nasr E, Faria S, Hay J, Larsson S, Shenouda G, Souhami L, Wong F, Freeman C. Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. Int J Radiat Oncol Biol Phys. 2004 Jul.59(3):809-814. Pubmedid: 15183484.
• Grigsby PW, Portelance L, Williamson JF. High dose ratio (HDR) cervical ring applicator to control bleeding from cervical carcinoma. Int J Gynecol Cancer. 2002 Jan.12(1):18-21. Pubmedid: 11913357.
• Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001 Sep.51(1):261-266. Pubmedid: 11516876.
• Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999 Oct.86(8):1528-1536. Pubmedid: 10526282.